| 000 | 01544cam a2200289 4500500 | ||
|---|---|---|---|
| 005 | 20250112040115.0 | ||
| 041 | _afre | ||
| 042 | _adc | ||
| 100 | 1 | 0 |
_aZerbib, Frank _eauthor |
| 700 | 1 | 0 |
_a Hagège, Hervé _eauthor |
| 245 | 0 | 0 | _aTreatment of eosinophilic esophagitis |
| 260 | _c2023. | ||
| 500 | _a53 | ||
| 520 | _aThe aim of treatment for eosinophilic esophagitis is to achieve both clinical and histological remission. It is assumed (though this has not been fully demonstrated) that histological remission may reduce the risk of the fibrotic evolution of the disease, that is, development of strictures and food impaction. International guidelines recommend three types of first-line treatment: proton pump inhibitors, topical steroids, and an elimination diet. The development of orodispersible budesonide tablets represents significant progress in the treatment of eosinophilic esophagitis. Esophageal dilation may be offered to patients with ongoing strictures despite therapy. | ||
| 690 | _adilation | ||
| 690 | _aeosinophilic esophagitis | ||
| 690 | _aproton pump inhibitors | ||
| 690 | _aelimination diet | ||
| 690 | _atopical steroids | ||
| 690 | _adilation | ||
| 690 | _aeosinophilic esophagitis | ||
| 690 | _aproton pump inhibitors | ||
| 690 | _aelimination diet | ||
| 690 | _atopic steroids | ||
| 786 | 0 | _nHépato-Gastro & Oncologie Digestive | 30 | 3 | 2023-03-02 | p. 359-363 | 2115-3310 | |
| 856 | 4 | 1 | _uhttps://shs.cairn.info/journal-hepato-gastro-et-oncologie-digestive-2023-3-page-359?lang=en |
| 999 |
_c175225 _d175225 |
||